It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Xlear’s Pre-EUA Request is based on recent studies showing the nasal spray is:
virucidal (it kills the virus);
antiviral (it blocks the adhesion of the virus to the nasal membrane, which is how most people get sick from COVID-19);
antibacterial against streptococcus bacteria, which is the leading cause of bacterial pneumonia (a COVID-19 complication linked to morbidity); and,
Reduces both the duration and severity of illness when used to treat COVID-19 patients.
Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal spray. “Xlear doesn’t require the EUA to be sold and used—we only need an EUA to be able to inform people about the benefits of using Xlear to protect themselves from COVID-19. It’s insane. Without the EUA, the Federal Trade Commission won’t let us simply inform people about new, published, independent scientific studies,” Jones added.
It really is a simple concept: 90% of the viral load is located in the nose and upper airway, and anything we can do to reduce that viral load is going to slow the spread and reduce symptoms.
e-purposing a commercially available nasal spray containing xylitol and grapefruit seed extract (GSE), namely Xlear Nasal Spray® (Xlear, Inc., American Fork, USA) could be used as an adjunct treatment of COVID-19. With a well-established safety profile, the components of this nasal spray have been studied and have been shown to have potential efficacy against viral pathogens, including coronavirus, and may potentially regulate pathways important in the initial entry of infection, replication, and systemic response to SARS-CoV-2. We present a series of three mild-moderate risks, symptomatic, COVID-19 patients, treated with the intranasal combination, as an adjuvant to their ongoing treatment, with rapid clinical improvement and shorten time to negativization on repeat intranasal swab test via PCR. No safety issues were noted during the course of treatment. Xlear nasal spray, containing xylitol plus GSE, given its established safety profile and compelling clinical results described here, could be a potential adjunct treatment option in mild-moderate COVID-19 cases.
originally posted by: Nyiah
a reply to: infolurker
I'll skip. Pet households really don't want nor need to gamble with xylitol products around animals (it's toxic, for the uninitiated pet owners out there)
Edit: And yes, there was a study a few years ago disputing that, but the vet and us aren't convinced. Half a dozen cats studied isn't a big enough sample group to bet with.